FutureMeds expands into Bulgaria
By the end of the year, FutureMeds plans to operate from 3 sites located in the biggest cities in Bulgaria.
Following successes in Poland and the United Kingdom, FutureMeds is expanding its Dedicated Research Site Network into Bulgaria, where, by the end of 2021, it will operate from 3 sites located in the biggest cities in the country.
Bulgaria is among the 20 most productive countries in the world for clinical trials, with the Bulgarian market currently valued at USD 330 million.
Recent improvements in the regulatory environment have alleviated roadblocks impeding the sector and the market has been growing steadily over the last 5 years.
The country offers great potential for Pharma and Contract Research Organizations and the presence of 3 FutureMeds sites will further strengthen the sector.